H2-Kk inhibitors refer to a class of chemical compounds designed to specifically target and modulate the activity of the H2-Kk molecule. H2-Kk is a major histocompatibility complex (MHC) class I protein, a critical component of the immune system responsible for presenting antigenic peptides to cytotoxic T cells. This presentation plays a crucial role in immune surveillance and the elimination of infected or aberrant cells. H2-Kk inhibitors are primarily used in research settings to manipulate and study the immune response at the molecular level.
These inhibitors are typically small organic molecules that can interfere with the binding of antigenic peptides to the H2-Kk molecule or disrupt its function in antigen presentation. By doing so, they allow researchers to investigate the precise mechanisms involved in immune recognition and activation. H2-Kk inhibitors have proven valuable tools for exploring the complexities of the immune system, shedding light on processes such as antigen processing and presentation, T-cell receptor recognition, and immune evasion strategies employed by pathogens and cancer cells. Researchers employ these inhibitors to dissect the intricacies of immunology and gain a deeper understanding of how the immune system identifies and eliminates threats to the body. They serve as essential reagents for experimental studies that aim to uncover novel insights into immune responses, informing the development of strategies for immune modulation in various contexts, although such applications are beyond the scope of their primary use as research tools.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $412.00 | 32 | |
Lapatinib is a tyrosine kinase inhibitor that targets EGFR and HER2 receptors, preventing their phosphorylation and downstream signaling, inhibiting cancer cell growth. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib is an EGFR inhibitor that competes with ATP for binding, blocking the autophosphorylation of EGFR and disrupting downstream signaling pathways. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
Erlotinib inhibits EGFR tyrosine kinase activity, blocking receptor autophosphorylation and inhibiting cell growth and angiogenesis in cancer. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Imatinib is a BCR-ABL tyrosine kinase inhibitor, disrupting the signaling cascade in leukemia cells and promoting apoptosis. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib inhibits multiple kinases involved in tumor angiogenesis and cell proliferation, particularly RAF kinase and VEGFR, leading to cancer growth inhibition. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $150.00 $920.00 | 5 | |
Sunitinib targets multiple receptor tyrosine kinases, including VEGFR and PDGFR, leading to inhibition of angiogenesis and tumor growth. | ||||||
Pazopanib | 444731-52-6 | sc-396318 sc-396318A | 25 mg 50 mg | $127.00 $178.00 | 2 | |
Pazopanib is a multi-kinase inhibitor that primarily targets VEGFR, PDGFR, and c-Kit, inhibiting tumor angiogenesis and proliferation. | ||||||
Vandetanib | 443913-73-3 | sc-220364 sc-220364A | 5 mg 50 mg | $167.00 $1353.00 | ||
Vandetanib is a tyrosine kinase inhibitor targeting VEGFR, EGFR, and RET, disrupting angiogenesis and cancer cell proliferation. | ||||||
XL-184 free base | 849217-68-1 | sc-364657 sc-364657A | 5 mg 10 mg | $92.00 $204.00 | 1 | |
Cabozantinib (XL-184 free base) inhibits multiple tyrosine kinases, including VEGFR2, MET, and AXL, suppressing tumor growth, angiogenesis, and metastasis. | ||||||
BIBF1120 | 656247-17-5 | sc-364433 sc-364433A | 5 mg 10 mg | $180.00 $315.00 | 2 | |
Nintedanib (BIBF1120) is a triple angiokinase inhibitor targeting VEGFR, PDGFR, and FGFR, blocking angiogenesis and fibrosis in various diseases. |